Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies
Authors:
- 1 August 2014
- journal article
- Published by Elsevier in Fertility and Sterility
- Vol. 102 (2) , 488-495.e3
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancerJournal of Assisted Reproduction and Genetics, 2012
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression ProfilingClinical Cancer Research, 2012
- Creating a Continuum of CareClinical Obstetrics and Gynecology, 2011
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2011
- Fertility Preservation in Women With Breast CancerClinical Obstetrics and Gynecology, 2010
- Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancerAnnals of Oncology, 2010
- Breast cancer in young women and its impact on reproductive functionHuman Reproduction Update, 2009
- Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)JNCI: Journal of the National Cancer Institute, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005